Hepatitis C: Estimating sales during 2013-22.
By Michael Haydock, Lead Analyst
27 August 2014
I am the Lead Analyst of the immunology and inflammation and infectious diseases and vaccines teams at Datamonitor Healt...
Read full bio
Due to the launch of interferon-free regimens, the hepatitis C market will experience a compound annual growth rate of 18.2% during 2013–22. With Sovaldi currently dominating the market across all genotypes, and Gilead’s successor Sovaldi/ledipasvir fixed-dose combination forecast to be adopted as the gold standard for GT-1 patients, competitors will struggle to differentiate their treatments.
Datamonitor Healthcare has used a patient-based approach to estimate the size of hepatitis C sales in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) during 2013–22.
How will our hepatitis C forecast report benefit you?
- Plan your market strategy
Understand the catalysts affecting sales trends in the hepatitis C market and how these will shift the focus of the market over the forecast period. This will allow you to plan for these changes in your market strategy.
- Predict market share
Identify the patient populations which have a vast amount of brand competition and those where competition is scarce, allowing you to predict market share and recognize subgroups with untapped potential.
- Identify market share
Examine the effect of the treatment shift to interferon-free regimens (all-oral regimens) and how this will affect marketed and pipeline drugs sales projections in the forecast period, allowing you to identify which brands will occupy the majority of the market share.
Key questions answered
- How will sales for GT-1/2/3 change during 2013–22?
- Which brands have we predicted will rise and fall throughout the forecast period and why?
- How will AbbVie and Bristol-Myers Squibb compete with Gilead’s Sovaldi/ledipasvir fixed-dose combination
|Drug List:||Companies Mentioned:|
Posted in Infectious Diseases.